Sight Sciences, Inc.
Sight Sciences develops and sells interventional ophthalmology technologies for eye care providers treating glaucoma and dry eye disease. Its Interventional Glaucoma segment offers the OMNI Surgical System, a single-use device that enables procedures to reduce eye pressure in adults with primary open-angle glaucoma, and the SION Surgical Instrument, used to remove trabecular meshwork tissue during eye surgery. Its Interventional Dry Eye segment sells the TearCare system, which applies heat to help clear meibomian gland obstructions in adults with evaporative dry eye disease caused by meibomian gland dysfunction. Sight Sciences primarily sells OMNI and SION in the United States to ambulatory surgery centers and hospital outpatient departments, and sells TearCare to optometry and ophthalmology practices. It also sells OMNI directly in the United Kingdom and Germany and through distributors in other European countries. The company is headquartered in Menlo Park, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $SGHT in the last 30 days.
See all $SGHT insider activity →Sight Sciences (SGHT) reported that CMS set the 2027 fee for TearCare SmartLids at $1,000, effective January 1. The company's average 12-month price target increased to $11, suggesting 14% upside from its recent close. Analysts maintain a Buy consensus.
Sight Sciences (SGHT) reported Q3 2026 record revenue and raised guidance, with full-year growth expected at 20%. Adjusted operating expenses rose 21% YoY to $24M, and net loss was $6.8M. The company noted sequential deceleration in IDE revenue growth and market access challenges for TearCare. Management emphasized growth momentum and market opportunities, but guidance for 2027 was not provided.
Sight Sciences, Inc. (SGHT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance MENLO PARK, Calif., November 4, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning SGHT (Sight Sciences, Inc.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 1 bearish.
Recent SGHT coverage spans regulation, earnings and financial news.
The new CMS code could improve reimbursement prospects, supporting a price increase.
Guidance suggests continued growth but modest OpEx increase, indicating potential upside if the company meets targets.
Guidance raise suggests stronger demand for its eye‑care platforms.
Buy rating and target may drive demand.
The product launch may generate modest upside if surgeons adopt the device, but impact is uncertain.
AlphAI scores every news story that mentions SGHT with an AI model for sentiment and relevance, and aggregates insider trades from Sight Sciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Sight Sciences (SGHT) reported that CMS set the 2027 fee for TearCare SmartLids at $1,000, effective January 1. The company's average 12-month price target increased to $11, suggesting 14% upside from its recent close. Analysts maintain a Buy consensus.
Sight Sciences (SGHT) reported Q3 2026 record revenue and raised guidance, with full-year growth expected at 20%. Adjusted operating expenses rose 21% YoY to $24M, and net loss was $6.8M. The company noted sequential deceleration in IDE revenue growth and market access challenges for TearCare. Management emphasized growth momentum and market opportunities, but guidance for 2027 was not provided.
Sight Sciences, Inc. (SGHT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance MENLO PARK, Calif., November 4, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused
Analysts initiated coverage on several companies: Piper Sandler rated Redwire Corp (RDW) Neutral with a $11 target, Cantor Fitzgerald rated Eloxx Pharmaceuticals (ELOX) Overweight, HC Wainwright rated Sight Sciences (SGHT) Buy with a $14 target, Goldman Sachs rated Anglogold Ashanti (AU) Buy with a $104 target, and Raymond James rated First Financial Bankshares (FFIN) Market Perform.
Sight Sciences (SGHT) launched the OMNI Ultra MIGS System, an implant-free device, at AAO 2026. The company aims to extend its OMNI platform in the MIGS category, with future success depending on surgeon adoption and reimbursement support, according to AI Analyst.
Sight Sciences (SGHT) announced the launch of the OMNI Ultra Surgical System, an advanced glaucoma treatment. The system will be showcased at the 2026 American Academy of Ophthalmology annual meeting. OMNI Ultra is designed to reduce intraocular pressure by addressing key areas of resistance in the eye's aqueous outflow pathway.
Several biotech stocks hit 52-week highs on September 29, 2026. Iovance (IOVA) rose 31% to $11.17, raising its revenue guidance to $410M-$420M. Xeris (XERS) reached $11.33, with updates on its XP-8121 program. AbCellera (ABCL) peaked at $14.82, with positive Phase 2 results for ABCL635. Grail (GRAL) hit $140.88 after FDA panel support for its Galieri test. Sight Sciences (SGHT) climbed to $9.71, reporting $23M in Q2 revenue, up 20% YoY.
Sight Sciences (SGHT) announced FDA expanded the TearCare System's use to improve meibomian gland function in adults with evaporative dry eye disease due to MGD. This makes TearCare the first treatment indicated for this purpose, according to the company. The update also includes optional debridement, enhancing its approach to treating the condition. SGHT reported Q2 2026 revenue growth and updated its full-year guidance earlier this month.
Sight Sciences (SGHT) announced FDA approval for its TearCare System to improve meibomian gland function in patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD). This makes TearCare the first and only treatment indicated for this purpose, expanding its market potential. The company's CEO and a medical expert highlighted the significance of this milestone in dry eye disease treatment.
Sight Sciences (SGHT) reported Q2 2026 revenue of $23.4M, up 20% y/y, driven by Interventional Glaucoma ($20.7M) and Interventional Dry Eye ($2.7M). Gross margin rose to 91% from 85%. Net loss was $4.4M. FY2026 revenue guidance raised to $88M-$92M; adjusted opex guidance lowered to $92M-$94M. Alcon patent appeal remains pending.
